Dr. Rani Bansal
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 99
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Boston University School of Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NC license 2022-00581 -
Internal Medicine Physician
MA license 267516 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 99
- Services billed
- 301
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 118 | 50 |
| New patient office or other outpatient visit, 60-74 minutes | 46 | 46 |
| Established patient office or other outpatient visit, 30-39 minutes | 33 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Raleigh, NC | 206 |
| Verzenio (abemaciclib) | 43 |
| Letrozole Other prescribers in Raleigh, NC | 36 |
| Ondansetron Hcl Other prescribers in Raleigh, NC | 36 |
| Prochlorperazine Maleate Other prescribers in Raleigh, NC | 31 |
| Dexamethasone Other prescribers in Raleigh, NC | 18 |
| Tamoxifen Citrate Other prescribers in Raleigh, NC | 18 |
| Ibrance (palbociclib) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $2,398 in total to this clinician.
| Gilead Sciences, Inc. | $2,330 |
|---|---|
| Genentech USA, Inc. | $68.00 |
| Consulting Fee | $2,180 |
|---|---|
| Food and Beverage | $218 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 18, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4283686;VEM US;12807348 | $2,180 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $366,164 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients
Genentech, Inc. - A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.